enquiry@pharmascroll.com
Mail Us
-
Synspira’s drug receives FDA Orphan Designation for Cystic Fibrosis treatment
- October 16, 2018
- Posted by: Pharmascroll
No CommentsSynspira,a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, announced that it has been granted Orphan Designation by the United States Food and Drug Administration (FDA) for poly (acetyl, arginyl) glucosamine (PAAG15A), for the treatment of cystic fibrosis. Synspira is developing PAAG15A as SNSP113, a potential
-
FDA Approves ORKAMBI in Cystic Fibrosis for Children Ages 2-5 Years
- August 13, 2018
- Posted by: Pharmascroll
Vertex Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF in this population. ORKAMBI oral granules
-
Boehringer Ingelheim to Develop novel Gene Therapy for Cystic Fibrosis
- August 7, 2018
- Posted by: Pharmascroll
Boehringer Ingelheim steps into the field of gene therapy, a focus area of its Research Beyond Borders initiative, with experienced partners, in an effort to bring to cystic fibrosis patients a long-term treatment aimed at correcting the underlying genetic causes of this devastating disease. Boehringer Ingelheim will collaborate with the UK Cystic Fibrosis Gene Therapy
-
Kalydeco (ivacaftor) Data Demonstrates Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of Cystic Fibrosis
- June 7, 2018
- Posted by: Pharmascroll
Data from KALYDECO® (ivacaftor) studies show the potential to modify the long-term progression of the disease Interim analysis of the ongoing extension study of tezacaftor/ivacaftor combination (approved in the U.S. as SYMDEKOTM) continues to demonstrate consistent safety and sustained benefits up to 48 weeks Studies of investigational triple combination regimens highlight continued progress toward developing medicines
-
Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
- April 30, 2018
- Posted by: Pharmascroll
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF). The first Phase 3 study will evaluate approximately 360 people with CF who have one copy of the F508del mutation and one minimal function mutation and is